Trials / Conditions / Carcinoma, Neuroendocrine

Carcinoma, Neuroendocrine

18 registered clinical trials studyying Carcinoma, Neuroendocrine — 5 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	A UGT1A1 Genotype-Directed Study of Belinostat Pharmacokinetics and Toxicity NCT06406465	National Cancer Institute (NCI)	Phase 2
Not Yet Recruiting	Trial of FOLFIRI + Zimberelimab + Domvanalimab vs FOLFIRI With a Hybrid Synthetic Control Arm in Second Line T NCT07337447	Hospices Civils de Lyon	Phase 2
Withdrawn	Defining the Clinical Potential of Mass Response As a Biomarker for Patient Tumor Sensitivity to Drugs NCT04985357	Travera Inc	—
Recruiting	A First-in-Human Phase I Trial With Antibody Drug Conjugate ADCT-701 in Neuroendocrine Tumors, Carcinomas and NCT06041516	National Cancer Institute (NCI)	Phase 1
Completed	Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance (TraveraRTGx) NCT05461430	Travera Inc	—
Recruiting	Tissue Procurement and Natural History Study of Neuroendocrine Neoplasms (NENs) Including Adrenocortical Carci NCT05237934	National Cancer Institute (NCI)	—
Terminated	Natural History Study of Children and Adults With Neuroendocrine Neoplasms (NEN)s NCT04488263	National Cancer Institute (NCI)	—
Completed	Secured Access to Pembrolizumab for Patients With Selected Rare Cancer Types NCT03012620	UNICANCER	Phase 2
Completed	Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Can NCT03037385	Hoffmann-La Roche	Phase 1 / Phase 2
Active Not Recruiting	Personalized PRRT of Neuroendocrine Tumors NCT02754297	CHU de Quebec-Universite Laval	Phase 2
Completed	An Open Label, Single-Centre, Pilot Study of Everolimus With EBRT for the Treatment of mNET Liver Metastasis NCT02205515	Sunnybrook Health Sciences Centre	Phase 1 / Phase 2
Completed	Trial of Topotecan With VX-970 (M6620), an ATR Kinase Inhibitor, in Small Cell Cancers and Extrapulmonary Smal NCT02487095	National Cancer Institute (NCI)	Phase 1 / Phase 2
Terminated	Study of Mutation-Targeted Therapy With Sunitinib or Everolimus in People With Advanced Low- or Intermediate-G NCT02315625	National Cancer Institute (NCI)	Phase 2
Completed	KPT-330 to Treat Poorly Differentiated Lung and Gastroenteropancreatic Tumors NCT02250885	Gabrail Cancer Center Research	Phase 2
Recruiting	A Trial to Assess the Safety and Effectiveness of Lutetium-177 Octreotate Therapy in Neuroendocrine Tumours NCT01876771	AHS Cancer Control Alberta	Phase 2
Completed	A Phase I Study of Belinostat in Combination With Cisplatin and Etoposide in Adults With Small Cell Lung Carci NCT00926640	National Cancer Institute (NCI)	Phase 1
Completed	TheraSphere for the Treatment of Liver Metastases NCT00511862	Boston Scientific Corporation	Phase 2
Completed	Irinotecan and Cisplatin for High Grade Neuroendocrine Carcinoma of the Gastrointestinal Tract NCT00353015	M.D. Anderson Cancer Center	Phase 2